Has the time come for routine use of amifostine in clinical radiotherapy practice?

Acta Oncologica

Volumn 42, Issue 1, 2003, Pages 2-3

  Lindegaard, Jacob Chr ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE;

CANCER CONTROL; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EDITORIAL; FOOD AND DRUG ADMINISTRATION; HUMAN; META ANALYSIS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RADIATION INJURY; RADIATION PROTECTION; RANDOMIZED CONTROLLED TRIAL; XEROSTOMIA;

AMIFOSTINE; CLINICAL TRIALS; HUMANS; NEOPLASMS; RADIATION-PROTECTIVE AGENTS; RADIOTHERAPY;

EID: 0037228387     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.1080/0891060310002159     Document Type: Editorial

References (10)

1. Kruse JJCM, Strootman EG, Wondergem J. Effects of amifostine on radiation-induced cardiac damage. Acta Oncol 2003; 42: 4-9.
2. Yuhas JM. Protective drugs in cancer therapy: optimal clinical testing and future directions. Int J Radiat Oncol Biol Phys 1982; 8: 513-7.
3. Hensley ML, Schuchter LM, Lindley C, et al. American Society of Clinical Oncology Clinical Practice Guidelines for the Use of Chemotherapy and Radiotherapy Protectants. J Clin Oncol 1999; 17: 3333-55.
4. Denekamp J, Stewart FA, Rojas A. Is the outlook grey for WR-2721 as a clinical radioprotector. Int J Radiat Oncol Biol Phys 1983; 9: 595-8.
5. Lindegaard JC, Grau C. Has the outlook improved for amifostine as a clinical radioprotector? Radiother Oncol 2000; 57: 113-8.
6. Dubray B, Dhermain F. In regard to Antonadou et al. IJROBP 2001; 51: 915. Int J Radiat Oncol Biol Phys 2002; 53: 1395-6.
7. Dubray B, Dhermain F. In regard to Antonadou et al. IJROBP 2001; 51: 915. Int J Radiat Oncol Biol Phys 2002; 53: 1395-6.
8. Brizel DM, Wasserman T, Henke M, et al. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 2000; 18: 3339-45.
9. Schuchter LM, Hensley ML, Meropol NJ, Winer EP. 2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2002; 20: 2895-903.
10. Phillips KA, Tannock IF. Design and interpretation of clinical trials that evaluate agents that may offer protection from the toxic effects of cancer chemotherapy. J Clin Oncol 1998; 16: 3179-90.